TScan Therapeutics Inc
TCRX1.665USD
+0.045+2.78%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
94.22MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über TScan Therapeutics Inc Unternehmen
TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of T cell receptor-engineered T cell (TCR-T), therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in clinical development for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to build its ImmunoBank, a collection of solid tumor targets across different Human leukocyte antigens (HLAs) types in the TCR field. The Company is advancing approximately six solid tumor programs: TSC-204, TSC-200, TSC-203, TSC-201, TSC-202 and TSC-205.
Unternehmensinformationen
BörsenkürzelTCRX
Name des UnternehmensTScan Therapeutics Inc
IPO-datumJul 16, 2021
CEOMr. Gavin Macbeath, Ph.D.
Anzahl der mitarbeiter194
WertpapierartOrdinary Share
GeschäftsjahresendeJul 16
Addresse830 Winter Street
StadtWALTHAM
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl02451
Telefon18573999500
Websitehttps://www.tscan.com
BörsenkürzelTCRX
IPO-datumJul 16, 2021
CEOMr. Gavin Macbeath, Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Zoran Zdraveski, J.D., Ph.D.
Dr. Zoran Zdraveski, J.D., Ph.D.
Chief Legal and Strategy Officer, Secretary
Chief Legal and Strategy Officer, Secretary
84.61K
+1694.13%
Mr. Gavin Macbeath, Ph.D.
Mr. Gavin Macbeath, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
49.77K
--
Mr. Garry A. Nicholson
Mr. Garry A. Nicholson
Independent Director
Independent Director
--
--
Mr. R. Keith Woods
Mr. R. Keith Woods
Independent Director
Independent Director
--
--
Dr. Stephen R. Biggar, M.D., Ph.D.
Dr. Stephen R. Biggar, M.D., Ph.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Jason A. Amello ,
Jason A. Amello ,
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Dr. Chrystal U. Louis
Dr. Chrystal U. Louis
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Katina Dorton
Ms. Katina Dorton
Independent Director
Independent Director
--
--
Dr. Barbara J. Klencke, M.D.
Dr. Barbara J. Klencke, M.D.
Independent Director
Independent Director
--
--
Dr. Gabriela Gruia, M.D.
Dr. Gabriela Gruia, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Zoran Zdraveski, J.D., Ph.D.
Dr. Zoran Zdraveski, J.D., Ph.D.
Chief Legal and Strategy Officer, Secretary
Chief Legal and Strategy Officer, Secretary
84.61K
+1694.13%
Mr. Gavin Macbeath, Ph.D.
Mr. Gavin Macbeath, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
49.77K
--
Mr. Garry A. Nicholson
Mr. Garry A. Nicholson
Independent Director
Independent Director
--
--
Mr. R. Keith Woods
Mr. R. Keith Woods
Independent Director
Independent Director
--
--
Dr. Stephen R. Biggar, M.D., Ph.D.
Dr. Stephen R. Biggar, M.D., Ph.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Jason A. Amello ,
Jason A. Amello ,
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Umsatzaufteilung
FY2025Q1
FY2024
FY2023
FY2022
FY2021
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
United States
2.17M
0.00%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Fri, May 16
Aktualisiert: Fri, May 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Lynx1 Capital Advisors LLC
15.19%
BVF Partners L.P.
9.35%
K2 HealthVentures LLC
6.89%
Adage Capital Management, L.P.
6.69%
Baker Bros. Advisors LP
5.32%
Other
56.56%
Aktionäre
Aktionäre
Anteil
Lynx1 Capital Advisors LLC
15.19%
BVF Partners L.P.
9.35%
K2 HealthVentures LLC
6.89%
Adage Capital Management, L.P.
6.69%
Baker Bros. Advisors LP
5.32%
Other
56.56%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
34.77%
Hedge Fund
23.77%
Venture Capital
19.29%
Investment Advisor/Hedge Fund
12.62%
Research Firm
2.10%
Individual Investor
0.39%
Bank and Trust
0.35%
Private Equity
0.09%
Pension Fund
0.02%
Other
6.59%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
191
48.87M
93.41%
-296.84K
2025Q1
198
46.53M
88.95%
-3.07M
2024Q4
184
47.92M
91.75%
+202.11K
2024Q3
172
45.30M
92.65%
-3.14M
2024Q2
147
48.79M
100.07%
+12.56M
2024Q1
110
39.09M
88.67%
+3.45M
2023Q4
95
36.63M
84.04%
+3.23M
2023Q3
84
33.69M
84.61%
-2.13M
2023Q2
78
32.77M
82.58%
-787.78K
2023Q1
72
14.05M
68.89%
-1.92M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Lynx1 Capital Advisors LLC
7.95M
15.19%
+2.59M
+48.32%
May 20, 2025
BVF Partners L.P.
4.89M
9.35%
+1.90M
+63.56%
Mar 31, 2025
K2 HealthVentures LLC
3.60M
6.89%
+2.90M
+414.67%
Dec 31, 2024
Adage Capital Management, L.P.
3.50M
6.69%
--
--
Mar 31, 2025
Baker Bros. Advisors LP
2.78M
5.32%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.61M
4.99%
-57.04K
-2.14%
Mar 31, 2025
The Vanguard Group, Inc.
2.36M
4.5%
-25.79K
-1.08%
Mar 31, 2025
Propel Bio Management, LLC
2.09M
3.99%
--
--
Mar 31, 2025
Pitango Venture Capital
2.08M
3.98%
+2.08M
--
Dec 31, 2023
Checkpoint Capital L.P.
2.02M
3.86%
+261.66K
+14.90%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
Simplify Propel Opportunities ETF
2.25%
iShares Health Innovation Active ETF
0.08%
iShares Micro-Cap ETF
0.01%
ProShares Ultra Nasdaq Biotechnology
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
iShares Biotechnology ETF
0.01%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
Proshares Ultra Russell 2000
0%
Mehr Anzeigen
Simplify Propel Opportunities ETF
Anteil2.25%
iShares Health Innovation Active ETF
Anteil0.08%
iShares Micro-Cap ETF
Anteil0.01%
ProShares Ultra Nasdaq Biotechnology
Anteil0.01%
Invesco Nasdaq Biotechnology ETF
Anteil0.01%
iShares Biotechnology ETF
Anteil0.01%
DFA Dimensional US Sustainability Core 1 ETF
Anteil0%
Dimensional US Core Equity 1 ETF
Anteil0%
DFA Dimensional US Core Equity Market ETF
Anteil0%
Proshares Ultra Russell 2000
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
